<DOC>
	<DOCNO>NCT00001075</DOCNO>
	<brief_summary>To determine whether administration highly active antiretroviral treatment regimen consist ritonavir ( ABT-538 ) , zidovudine ( AZT ) , lamivudine ( 3TC ) associate restoration delay type hypersensitivity lymphocyte proliferative response patient moderately advance HIV-1 infection . To good characterize patient phenotype expand lymphocyte subpopulation , well genotype , phenotype , cellular origin virus persist initiation therapy , genotype phenotype drug-resistant isolates emerge therapy . Although plasma viral load drop dramatically initiation powerful antiretrovirals , drop zero . It appear new steady state reach , suggest reservoir may exist virus-producing cell , possibly cell monocyte/macrophage lineage , continue produce low level virus despite antiretroviral treatment .</brief_summary>
	<brief_title>The Effectiveness Ritonavir Plus Zidovudine Plus Lamivudine HIV-Infected Patients</brief_title>
	<detailed_description>Although plasma viral load drop dramatically initiation powerful antiretrovirals , drop zero . It appear new steady state reach , suggest reservoir may exist virus-producing cell , possibly cell monocyte/macrophage lineage , continue produce low level virus despite antiretroviral treatment . Patients undergo 5 week antiretroviral washout initiate therapy ritonavir alone 9 day , follow combination therapy ritonavir , zidovudine , lamivudine day 10 week 48 . [ AS PER AMENDMENT 1/31/97 : The availability current , open-label study treatment extend allow patient complete 48 week therapy continue protocol therapy last enrolled patient complete 48 week study treatment . ]</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Recombinant erythropoietin and/or GCSF AZTrelated bone marrow suppression . Antibiotics metronidazole . PCP prophylaxis . Regularly prescribed medication antipyretic , analgesic , allergy medicine , oral contraceptive . Vitamins herbal therapy . Concurrent Treatment : Allowed : Acupuncture . Visualization technique . Patients must : Documented HIV infection . CD4 count 100300 cells/mm3 . At least 3 consecutive month prior AZT dosage 500600 mg bid , 5 week antiretroviral washout prior study entry . Consent parent guardian le 18 year old . Prior Medication : Required : Prior AZT 500600 mg bid time . PCP prophylaxis antiretroviral washout . Allowed : Prior ddI and/or ddC . Prior recombinant erythropoietin and/or GCSF AZTrelated bone marrow suppression . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Chronic pancreatitis . Psychological condition would affect compliance . Intolerance 500600 mg/day AZT . Concurrent participation another antiretroviral research treatment study ( study treatment opportunistic infection complication HIV allow ) . Considered likely noncompliant study . Concurrent Medication : Excluded : Immunomodulators systemic corticosteroid , thalidomide , cytokine . Rifabutin . Disulfiram ( Antabuse ) medication similar effect , include metronidazole . Other drug contraindicate ritonavir . [ AS PER AMENDMENT 8/27/96 : Immunization must avoid antiretroviral washout period . ] Patients follow prior condition exclude : Active opportunistic infection febrile illness temperature &gt; = 38.5 C within 3 day prior study entry . History acute pancreatitis within past 2 year . Prior Medication : Excluded : Prior 3TC protease inhibitor . Experimental drug except HIVrelated condition , within past 30 day . [ AS PER AMENDMENT 8/27/96 : Immunization must avoid prior antiretroviral washout period . ] Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Lamivudine</keyword>
</DOC>